SBBP - Strongbridge highlights post hoc analyses from KEVEYIS PPP open label study

Strongbridge Biopharma (SBBP) announces that post hoc analyses from a one year open-label study evaluating daily use of KEVEYIS (dichlorphenamide) for the treatment of Primary Periodic Paralysis ((PPP)) following a nine-week randomized, controlled study were published in the peer-reviewed journal, Muscle & Nerve. The company's chief medical officer Fredric Cohen said that the analysis showed that KEVEYIS' efficacy was maintained over the entire 61-week study with no evidence of waning over time.The results confirmed that long-term treatment with KEVEYIS is safe and effective for chronic use.Adverse event analyses indicated no new safety signals during the final 52 weeks of the study versus the first nine weeks, with the common adverse events of paresthesia and cognition impairment, reported at lower frequencies during the extension as compared with the first 9 weeks.PPP is a life-long rare, hereditary skeletal muscle disorder that leads to debilitating attacks of muscle weakness.Shares down 1% premarket.

For further details see:

Strongbridge highlights post hoc analyses from KEVEYIS PPP open label study